Current diagnosis and management of Crohn's disease in China: results from a multicenter prospective disease registry

BMC Gastroenterol. 2019 Aug 16;19(1):145. doi: 10.1186/s12876-019-1057-2.

Abstract

Background: This study aimed to understand the disease characteristics and treatment outcomes of Crohn's disease (CD) in a real-world setting in China.

Methods: In this prospective, non-interventional, multicenter disease registry, adults (≥18 years) with existing and newly diagnosed CD were recruited from 14 medical centers across China from January 2015 to January 2017. The study consisted of the enrollment and follow-up periods, of 12 months each. Demographic, clinical characteristics, diagnostic duration and management of CD at enrollment were evaluated. Logistic regression analysis and stepwise multivariate logistic regression analysis used to assess the relationship between the risk factors and CD.

Results: Of 504 enrolled patients, 499 (99.0%) were eligible for analysis. The mean (SD) age at study enrollment was 32.3 (11.43) years and the majority (69.7%) of participants were male. In the past 15 years, a sustained decrease of the period of time in the diagnosis of CD was observed, at about 39.4 (24.11) months in 2010, which decreased to 3.1 (2.13) months in 2015. The most common presenting symptoms of CD included abdominal pain (78.0%), diarrhea (58.1%), weight loss (52.9%) and fever (30.1%). Oral ulcer (19.4%) and arthritis (9.8%) were the most common extra-intestinal manifestations. Non-stricturing non-penetrating (B1) (49.9%) behavior and ileocolonic involvement (L3) (56.2%) location were more frequent. Perianal disease was observed in 29.1% of the patients. Around 23.8% (119/499) patients had CD-related surgery other than perianal disease surgery. Older age at enrollment, longer disease course, complicated disease behavior and absence of perianal disease were all surgery risk factors (p < 0.05). The most common medications was immunomodulators (e.g., azathioprine) (41.5%), anti-TNFα agents (32.9%) and aminosalicylates (20.6%). The mean (SD) Crohn's Disease Active Index (CDAI) score was 159.1 (91.45) and almost half of the patients (49.1%, 81/165) were in remission.

Conclusions: This study demonstrated the CD-disease characteristics, risk factors of CD-related surgery and perianal disease, and treatment strategies in a real-world setting in China and may help in developing programs to diagnose and manage patients with CD.

Keywords: China; Crohn’s disease; Disease registry; Extraintestinal manifestations; Treatment outcomes.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • China / epidemiology
  • Crohn Disease* / diagnosis
  • Crohn Disease* / epidemiology
  • Crohn Disease* / physiopathology
  • Crohn Disease* / therapy
  • Disease Progression
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Male
  • Middle Aged
  • Needs Assessment
  • Outcome and Process Assessment, Health Care
  • Patient Acuity
  • Patient Care Management* / methods
  • Patient Care Management* / statistics & numerical data
  • Registries / statistics & numerical data
  • Risk Factors
  • Time-to-Treatment / statistics & numerical data

Substances

  • Immunologic Factors